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Abstract
Background: To understand the current state of insufficient drug efficacy experienced by patients with Parkinson’s
disease (PD) and its effects on quality of life (QOL), we conducted a survey of patients with PD and analyzed the
results from 2,630 completed questionnaires.
Methods: The questionnaires inquired about age, sex, Hoehn and Yahr stage, disease duration, drugs currently
being taken, and the current state of insufficient drug efficacy; it also included items of the Parkinson’s Disease
Questionnaire-8 (PDQ-8). Questionnaires were mailed to members of the Japan Parkinson’s Disease Association.
Results: Approximately 70 % of all subjects reported some type of insufficient drug efficacy, and around half of
these experienced this early in the morning or at night. The proportion of subjects who experienced insufficient
drug efficacy was found to increase with greater disease severity according to the Hoehn and Yahr stage. However,
even among patients with stage I severity, insufficient drug efficacy was reported by approximately 40 % of the
respondents. QOL was significantly lower in patients who experienced insufficient drug efficacy than in those who
did not (PDQ-8 summary index; 42.0 ± 20.1 vs. 30.0 ± 19.5; p < 0.0001).
Conclusions: These results suggest that insufficient drug efficacy might affect the quality of life of patients in most
stages PD including the early stages. Therefore, greater awareness of insufficient drug efficacy gained by
questioning patients might help medical practitioners in taking appropriate actions.
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Background
Parkinson’s disease (PD), a progressive neurodegenera-
tive disease, has the second highest prevalence in the
elderly population after Alzheimer's dementia. It affects
approximately 141,000 people in Japan [1], although this
number will likely increase further as the Japanese popu-
lation continues to age rapidly [2]. Recent advances have
been made in pharmacotherapies available for PD, such
as antiparkinson agents, which mainly include dopamin-
ergic drugs such as levodopa. Dopaminergic medications
offer favorable and stable effects in the first few years of
administration—called the honeymoon period. However,
motor fluctuations such as “wearing-off” and dyskinesia,
may develop as complications of long-term treatment of
levodopa [3]. It has been reported that such motor com-
plications affect the patient’s quality of life (QOL) to a
great degree [4]. Improvements in accuracy of PD diagno-
sis and treatment have led to prolonged life expectancy in
patients with PD, which is nearly identical to that of
healthy individuals. Therefore, QOL improvement is now
an important issue while planning treatment. Inappropri-
ate pharmacotherapy or insufficient management of
wearing-off can lead to insufficient drug efficacy [5]. To
investigate the frequency of insufficient drug efficacy dur-
ing the day and night and the extent to which insufficient
drug efficacy impairs QOL, we surveyed patients with PD
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Methods
The protocol used for the study was approved by the Eth-
ics Committee of Fukuoka University Hospital (Fukuoka,
Japan). Questionnaires were mailed to 8,001 members (as
of August 2012) of the Japan Parkinson’s Disease Associ-
ation by the secretariat of the association, along with the
association’s bulletin. The questionnaire was devised spe-
cifically for use in this study. Completed questionnaires
and written consent to participate in this study were
returned through mail by the respondents. The survey
was conducted from August 13 to October 10, 2012. The
attributes of patients surveyed in the questionnaire were
age, sex, Hoehn and Yahr stage [6], duration of the disease
(<3 years, 3–7 years, or ≥7 years), and the names of drugs
currently being taken. QOL was evaluated using the Par-
kinson’s Disease Questionnaire-8 (PDQ-8) [7, 8]. The
current state of insufficient drug efficacy was investigated
with the following questions: (1) “Does it take time for the
drugs to take effect? (yes, no),” (2) “When does the drug
take effect during the day? (Early morning, during the day,
night; multiple answers possible)” and (3) “What difficul-
ties are caused when insufficient drug efficacy occurs?
(Multiple choice, multiple answers possible).”
The results of the survey were then analyzed. The re-
sults of whether subjects were troubled by insufficient
drug efficacy, at what period(s) they were troubled by in-
sufficient drug efficacy, and what issues were caused by
insufficient drug efficacy were documented for all sub-
jects and then classified according to the Hoehn and
Yahr stages. For the period(s) when subjects were trou-
bled by insufficient drug efficacy, only responses of “dur-
ing the day” were counted as “insufficient drug efficacy
during the day only” and those of “early morning” and
“night” were considered “insufficient drug efficacy dur-
ing early morning and at night.” Descriptive statistics
were calculated for each of the eight items included in
the PDQ-8. The PDQ-8 summary index (PDQ-8-SI) was
also calculated for each subject, and descriptive statistics
for all subjects were evaluated among groups according
to the presence or absence of a period of insufficient
drug efficacy. The PDQ-8-SI is derived by the sum of
PDQ-8 scale scores divided by eight (the number of
scales), which yields a score between 0 and 100. In this
score, higher the number, more numerous are the health
problems [9]. The Student’s t-test was used to compare
the mean PDQ-8-SI scores according to the presence or
absence of a period when the subjects were troubled by
insufficient drug efficacy and according to the actual
time of the day when they were troubled by insufficient
drug efficacy. The level of significance was set at p < 0.05
for all tests. We also performed multivariate statistics
using the general linear model (GLM) to evaluate
whether insufficient drug efficacy influenced PDQ-8-SI
after adjustment for several confounding factors (e.g.,
age, gender, Hoehn and Yahr stage, and duration of the
disease). If we found a factor that had a significant inter-
action with insufficient drug efficacy, we performed a
model design that included that interaction term. Gender
and Hoehn and Yahr stage were set as the categorical scale,
age as the metric scale, and disease duration as the ordinal
scale variables of < 3 year = 0, ≧ 3– < 7 year = 1, ≧ 7 = 2.
Results
Responses were received from 2,632 patients during the
survey period. Of these, 2,630 responses were considered
valid responses, as two blank questionnaires were ex-
cluded. Table 1 lists the attributes of patients. The mean
age of the patients was 70.7 years, and women accounted
for 54.1 % of the respondents. The most common Hoehn
and Yahr stage was stage III (36.5 %), followed by stage IV
(12.2 %), stage II (7.9 %), stage V (3.5 %), and stage I
(2.9 %). The stage of severity was unclear for 37.0 % of
subjects. The most common response for duration of the
disease was ≥7 years (63.7 %).
Of the 2,630 respondents who returned completed
questionnaires, 73.4 % responded that there were periods
when they were troubled by insufficient drug efficacy. Ac-
cording to the Hoehn and Yahr stage, a greater proportion
of patients with higher stages of severity responded that
there were periods when they were troubled by insuffi-
cient drug efficacy. However, the proportion of subjects at
stage V was lower than that of subjects at stage IV. With
respect to the periods of insufficient drug efficacy, 31.8 %
of all subjects responded that they experienced “insuffi-
cient drug efficacy during the day only,” while 39.8 %
responded that they experienced “insufficient drug efficacy
during early morning and at night.” Therefore, more sub-
jects experienced insufficient drug efficacy during early
morning and at night than during the day only. However,
this trend did not exhibit any correlation with severity of
the disease (Fig. 1).
The most frequent response to problems caused by in-
sufficient drug efficacy was “cannot work/do housework”
(58.7 %), followed in order by “cannot go out” (57.5 %)
and “worry about when the drug(s) will stop having ef-
fects” (54.4 %). Furthermore, greater severity of the dis-
ease led to higher proportions of subjects responding,
“cannot go out,” “causing trouble to my family,” and “I
lose the ability to move when I am alone” (Fig. 2).
The mean (± standard deviation) PDQ-8-SI was 38.9 ±
20.7, and PDQ-8-SI scores increased with higher Hoehn
and Yahr stages. The mean score for subjects who experi-
enced insufficient drug efficacy was significantly higher
than the score for those who did not (42.0 ± 20.1 vs. 30.0 ±
19.5; p < 0.0001; t-test). When divided according to Hoehn
and Yahr stages, a significant difference was also observed
for subjects with Hoehn and Yahr stages I–III (Table 2).
We also found that PDQ-8-SI scores were significantly
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higher in subjects who experienced “insufficient drug effi-
cacy during early morning and at night” than in those who
experienced “insufficient drug efficacy during the day only”
(43.3 ± 20.7 vs. 40.7 ± 19.2; p = 0.0092; t-test) (Table 3). Ac-
cording to Hoehn and Yahr stage, subjects with stages I–II
and those who responded that they experienced “insuffi-
cient drug efficacy during early morning and at night”
tended to have higher scores (Table 3). The highest mean
PDQ-8 scores for divided items were for mobility,
followed by activities of daily living and emotional well-
being (Table 4).
The result of a GLM analysis is shown in Table 5. We
performed this analysis to evaluate the impact of insuffi-
cient drug efficacy on the PDQ-8-SI. We found a signifi-
cant difference between the interaction term of insufficient
drug efficacy +Hohen and Yahr stage and PDQ-8-SI ac-
cording to the GLM analysis including all interaction terms
(P = 0.0218, data not shown). Table 5 presents these inter-
action terms (insufficient drug efficacy +H & Y stage).
These analyses confirmed that insufficient drug effi-
cacy has a significant effect on PDQ-8-SI, independent
of confounding factors such as age, gender, Hoehn and
Yahr stage, and duration of the disease; PDQ-8-SI of in-
sufficient drug efficacy with a “Yes” response was 13.12
(95 % CI:8.30,17.94) higher than that with a “No” re-
sponse to insufficient drug efficacy (p < 0.001). However,
we also found a significant interaction between insuffi-
cient drug efficacy and Hoehn and Yahr stage; Hoehn
and Yahr stage group of ≧ 3 found PDQ-SI increasing
score reduced 5.71(95 % CI: 2.81, −11.22) compared to
Hoehn and Yahr stage group of <3.
Discussion
In the present study, approximately 70 % of all patients
with PD responded that there were “periods when they
were troubled by insufficient drug efficacy.” Moreover,
among patients who were classified to be at Hoehn and
Yahr stage I, approximately 40 % felt insufficient drug ef-
ficacy during the daytime and/or nighttime. Stacy et al.
[10] investigated the prevalence of wearing-off in patients
with PD treated with levodopa for ≤5 years using the
Wearing-off Questionnaire-32 (WOQ-32). They found
that 57 % of subjects experienced wearing-off, although
physicians recognized the presence of wearing-off only in
40 % of patients, indicating a significant deviation from re-
ports by physicians about whether wearing-off was present
Table 1 Patients’ characteristics
Characteristics
Age, mean ± SD years, (n) 70.7 ± 7.9 (n = 2530)
Gender, n (%) Female : 1424 (54.1 %)
Male : 1100 (41.8 %)
Non-response : 106 (4.0 %)
Employment status, n (%) Employed : 186 (7.1 %)
Helping with the
housework
: 288 (11.0 %)
Unemployed : 2095 (79.7 %)
Non-response : 61 (2.3 %)
Necessity of caregiving,
n (%)
Not requiring caregiving : 981 (37.3 %)
Requiring partial
caregiving
: 1317 (50.1 %)
Requiring total caregiving : 286 (10.9 %)
Non-response : 46 (1.7 %)
Type of institutions which
the patients attend for
treatment, n (%) -multiple
answers allowed-
University hospital : 581 (22.1 %)
Hospital except for
university hospitals
: 1475 (56.1 %)
Clinic : 572 (21.7 %)
Not attending any
medical institutions
: 24 (0.9 %)
Others : 137 (5.2 %)
Non-response : 34 (1.3 %)
Duration of Parkinson’s
disease, n (%)
<3 years : 221 (8.4 %)
3-7 years : 681 (25.9 %)
≥7 years : 1675 (63.7 %)
Unknown : 53 (2.0 %)
Hoehn and Yahr stage,
n (%)
Stage I : 76 (2.9 %)
Stage II : 207 (7.9 %)
Stage III : 959 (36.5 %)
Stage IV : 322 (12.2 %)
Stage V : 92 (3.5 %)
Unknown : 974 (37.0 %)
Officially acknowledged
patient with the specific
disease, n (%)
Yes : 2157 (82.0 %)
No : 380 (14.4 %)
Non-response : 93 (3.5 %)
Anti-parkinsonian
medication, n (%) -
multiple answers
allowed-
Levodopa : 1667 (63.4 %)
Pramipexole IR : 1076 (40.9 %)
Pramipexole ER : 215 (8.2 %)
Ropinirole : 474 (18.0 %)
Cabergoline : 294 (11.2 %)
Pergolide : 294 (11.2 %)
Bromocriptine : 58 (2.2 %)
Table 1 Patients’ characteristics (Continued)
Entacapone : 945 (35.9 %)
Selegiline : 918 (34.9 %)
Zonisamide : 460 (17.5 %)
Others : 1427 (54.3 %)
Non-response : 166 (6.3 %)
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Fig. 1 The proportion of patients experienced insufficient efficacy of anti-parkinson medication depend on the time zone stratified by Hoehn
&Yahr stages: Data excluding107 patients without response to the question about insufficient efficacy of medication. Data excluding 976 patients
with answer as unclear to Hoehn and Yahr stage from stratified analysis
Fig. 2 Inconveniences due to experienced insufficient efficacy of anti-parkinson medication: Data excluding 624 patients with answer as unclear
to Hoehn and Yahr stage from stratified analysis
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or not. Wearing-off is generally recognized as a complica-
tion in the progressive stage of PD [11]. However, insuffi-
cient drug efficacy experienced by subjects in relatively
early stages in the present study indicated the possibility
of under-medication in which the duration of the effect or
dosage was insufficient. These findings suggest the im-
portance of proactively confirming drug efficacy and iden-
tifying effects of medical treatment on QOL. Our results
also indicate an overall high frequency of insufficient drug
effects, including subjects with advanced stages of PD.
This could be due to not only an increase in wearing-off
but also because patients compared current with past drug
efficacy. These results may also be reflective of the pa-
tients’ dissatisfaction with their current disease states. In
any case, appropriate questioning of patients by physicians
is crucial to understand their current state and to offer
treatment with suitable medications.
Our survey also revealed that the frequency of re-
sponses to items related to motor symptoms, such as
“cannot go out” and “I lose the ability to move when I
am alone,” increased in patients with higher stages of se-
verity. The item “worry about when the drug(s) will stop
having effects” had a high frequency, regardless of the
stage of severity, even in subjects with early stages of
PD. As this was the most common response to problems
caused by insufficient drug efficacy by subjects with
Hoehn and Yahr stage I, it appears that patients with
early stages of PD require sufficient explanation and psy-
chological support. Furthermore, the highest proportion
of subjects who responded that they “cannot work/do
housework” occurred among subjects with Hoehn and
Yahr stage II. Thereafter, the proportion decreased with
greater severity of the disease. These results suggest the
need for treatment that takes the social environment of
the patient into consideration.
The results of the present study indicated that more
than half of patients who responded that there were pe-
riods when they were troubled by insufficient drug effi-
cacy replied that they were troubled not only during the
day but during early morning and at night as well. These
results were the same for subjects with Hoehn and Yahr
stage I. Although nighttime and early morning symp-
toms have conventionally been considered a problem for
patients with advanced stages of PD, these symptoms
also occur in patients with early stages of PD. Patients
who experience insufficient drug efficacy at night or dur-
ing early morning had significantly higher PDQ-8-SI
scores than those who did not. These patients were also
Table 3 Patients’ Quality of Life based on the time zone showing insufficient efficacy of anti-parkinsonian medication
Only in the daytime zone In the time zone of sleeping and early morning with and without daytime p
valuean PDQ-8-SI n PDQ-8-SI
747 40.7 ± 19.2 924 43.4 ± 20.7 0.0092
Hoehn &Yahr stages
Stage I 13 28.6 ± 20.2 16 41.2 ± 22.4 0.1269
Stage II 49 35.9 ± 19.4 68 40.4 ± 21.4 0.2460
Stage III 319 37.6 ± 17.5 368 38.9 ± 17.4 0.3273
Stage IV 109 46.4 ± 17.6 136 49.9 ± 20.1 0.1460
Stage V 22 63.1 ± 22.0 33 71.3 ± 21.7 0.1761
Data excluding 41 patients without response on the time zones and with insufficient efficacy of medication. Data are expressed as numbers of patients , mean ±
SD, or p values
a:student t-test (comparison between the two groups)
Table 2 Comparison of PDQ-8-Summary Index between patient groups with and without insufficient efficacy of medication
Total Patients with insufficient efficacy Patients without insufficient efficacy p
valuean PDQ-8-SI n PDQ-8-SI Number PDQ-8-SI
Total 2422 38.9 ± 20.7 1712 42.0 ± 20.1 625 30.0 ± 19.5 <0.0001
Hoehn &Yahr stages
Stage I 75 26.7 ± 19.2 29 35.6 ± 22.0 42 19.6 ± 14.5 0.0004
Stage II 194 32.6 ± 20.1 118 38.3 ± 20.6 71 24.3 ± 15.5 <0.0001
Stage III 907 36.8 ± 17.8 697 38.3 ± 17.5 180 31.0 ± 18.2 <0.0001
Stage IV 300 48.0 ± 19.2 251 48.2 ± 19.2 39 45.8 ± 20.0 0.4557
Stage V 77 65.5 ± 23.0 59 67.4 ± 21.5 12 51.3 ± 25.5 0.0246
Data excluding 208 patients without response on PDQ-8-Summary Index and 85 patients without response on experienced insufficient efficacy of medication. Data
are expressed as numbers of patients, mean ± SD, or p values
a:student t-test (comparison between the two groups)
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likely to have lower QOL. Chapuis et al. [12] conducted
an evaluation using the PDQ-39 SI and reported that the
presence of nighttime and early morning motor complica-
tions significantly compromised QOL. In particular, im-
mobility during the night exacerbated all eight dimensions
included in the PDQ-39. Havlikova et al. [13] reported
that sleep disorders affected QOL and insufficient drug ef-
ficacy at night and during early morning reduced the
amount of good quality sleep, thereby reducing QOL.
This study is based on objective evaluation of the pa-
tients; therefore, “insufficient drug efficacy” in this study
includes various factors such as under medication caus-
ing inadequate dopaminergic stimulation, which affects
patients both in the daytime and early morning, and
wearing-off phenomenon only affects in the daytime.
We should recognize the necessity to resolve these prob-
lem in each patient.. It is not clear whether insufficient
drug efficacy during the day, night, or early in the morn-
ing has the most effect on QOL.
Here, we used the PDQ-8 to evaluate QOL. The PDQ-
8 questionnaire is a shortened version of PDQ-39 and
has been established as an index to evaluate the QOL of
patients with PD [14]. However, no previous used the
PDQ-8 to investigate Japanese subjects. In the present
study, the mean PDQ-8-SI score was 38.9, which was
higher than that reported in a validation study1 (mean
score, 27.16). The higher score in the present study may
have been due to effects of disease severity. Factors af-
fecting QOL include Hoehn and Yahr stage, UPDRS part
III score, and duration of the disease [8]. The mean
Hoehn and Yahr stage for Japanese patients included in
a previous validation study was 2.85 ± 0.95, while the
mean severity stage for subjects in the present study was
3.09 ± 0.85, with patients at stage IV or stage V account-
ing for 15.7 % of all subjects. Scores for patients with
Hoehn and Yahr stages II and III were consistent with
those reported in a study conducted overseas [15].
In the present study, when PDQ-8-SI scores were
assessed according to severity of the disease, we found
that QOL was lower in patients who experienced insuffi-
cient drug efficacy, regardless of disease severity. In par-
ticular, QOL was significantly lower in patients who
experienced insufficient drug efficacy and who had
Hoehn and Yahr stages I-III. Among patients at stage I,
the mean PDQ-8-SI score was 35.6 ± 22.0 for individuals
who responded that they experienced insufficient drug
efficacy and 19.6 ± 14.5 for those who responded that
they did not. According to Jenkinson et al. [8], the mean
PDQ-8-SI score for patients at stage I was 17.74, sug-
gesting that insufficient drug efficacy may affect QOL.
Stacy et al. [16] reported that motor complications de-
creased QOL. However, according to an investigation by
Marras et al. [17], motor complications did not largely
influence the QOL of patients with early stages of PD.
There were limitations to the interpretation of the
present results because other factors that could affect
QOL were not examined. However, when patients with
identical disease severity were examined, those who ex-
perienced insufficient drug efficacy had significantly
lower QOL. This suggests that when prescribing medica-
tions, physicians should consider the fact that motor
complications such as wearing-off affect QOL even in
patients with early stages of PD.
Our results revealed no statistical difference of PDQ-8
SI between patients with and without insufficient effi-
cacy only in patients at the Yahr 4 stage. It is speculated
that majority of patients with the Yahr 4 stage would
Table 5 Multivariate statistical analysis for PDQ-SI(General linear
model)
Parameter B SE 95 % CI p value
Insufficient drug efficacy
No Reference
Yes 13.12 2.46 8.30 , 17.94 0.000
Hoehn and Yahr stage
<3 Reference
>3 8.69 2.26 4.25 , 13.12 0.000
Gender
Male Reference
Female −2.01 1.01 −3.98 , −0.03 0.046
Age 0.44 0.07 0.31 , 0.57 0.000













−5.71 2.81 −11.22 , −0.19 0.042
B regression coefficient; 95 % CI 95 % confidence interval; SI standard error;
GLM General linear model; H&Y Hoehn and Yahr stage
Table 4 Average scores of eight discrete scales in PDQ-8
Category in PDQ-8 (n = 2422)
Mobility 2.1 ± 1.3
Activities of daily living 2.0 ± 1.2
Emotional well being 1.8 ± 1.1
Social support 1.0 ± 1.2
Cognitions 1.5 ± 1.1
Communication 1.4 ± 1.2
Bodily discomfort 1.4 ± 1.2
Stigma 1.1 ± 1.1
Data excluding 208 patients with missing data on PDQ-8. Data are expressed
as mean ± SD
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develop the wearing-off effect and be aware of these
symptoms disturbing their quality of life (QOL). There-
fore, the physician needs to increase the dose of dopa-
minergic medication including L-DOPA and dopamine
agonists. In addition, there is a possibility that non-
motor symptoms, which are not resolved with dopamin-
ergic medication, strongly affect the QOL of patients.
These non-motor symptoms could decrease the QOL of
both patients with and without insufficient drug efficacy.
The questionnaire used in the present study to survey
patients may have led to some variation because of indi-
vidual interpretations by the respondents. Moreover, as
there were limits to the items that could be surveyed, it
was not possible to assess all factors that affect QOL. Fur-
thermore, because this survey was voluntary, the question-
naire recovery rate was only 32.9 %. However, the results
clarified that insufficient drug efficacy occurred at a high
frequency from early stages in over 2,600 patients with
PD, with no restrictions on age or severity of the disease,
and had a detrimental influence on QOL.
This study included few patients with the mild stage of
the disease possibly because the support group (Japan
Parkinson’s Disease Association) itself included fewer pa-
tients in the mild stage of the disease. However, we could
not rule out the possibility that fewer patients in the mild
stage participated in our study because of lack of motiv-
ation to respond to the survey. If this were the case, it
could account for the higher frequency of insufficient drug
efficacy in the mild PD population included in this study.
The large sample size could definitely lower the chance
of random errors; however, because of the study design,
one other limitation is the possibility of systematic errors
or biases, such as information bias. Therefore, further
studies should be performed to validate our findings.
Conclusions
The results of the present study indicated that nearly 70 %
of all our patients with PD and approximately 40 % of
those with Hoehn and Yahr stage I experienced insuffi-
cient drug efficacy. The results also indicated that more
than half of these patients experienced insufficient drug
efficacy not only during the day but also at night and in
the early morning. QOL was significantly decreased in pa-
tients who responded that they were troubled by insuffi-
cient drug efficacy. Therefore, physicians should question
patients regarding insufficient drug efficacy at night and
during early morning. Further studies on this topic are
needed to help facilitate better QOL in patients with PD.
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